Drug Trial Radar · NCT05871541
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
May 26, 2023
Primary completion
Mar 25, 2024
Study completion Mar 25, 2024
Sponsor
- Lead sponsor
- Immorna Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 69 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either JCXH-105 or Shingrix.
Conditions
- Herpes Zoster (HZ)
- Shingles
- Infectious Disease
Interventions
JCXH-105Biological
As IM injection
Active Control (Shingrix)Biological
As IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAE FrequencyTime frame: Day 1 - Day 241
- Injection site reactionTime frame: 7 days after the first and second vaccination
- Solicited systemic reaction frequencyTime frame: 7 days after the first and second vaccination
- AE frequencyTime frame: 30 days after the first and second vaccination
- Medically attended AE frequencyTime frame: Day 1 - Day 241
- The frequency of potential immune-mediated adverse events"Time frame: Day 1 - Day 241
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CenExel RCA
Hollywood, Florida
CenExel FCR
Tampa, Florida
CenExel HRI
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.